Business Description
BioAtla Inc
NAICS : 541714
SIC : 2833
ISIN : US09077B1044
Share Class Description:
BCAB: Ordinary SharesDescription
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 45.18 | |||||
| Equity-to-Asset | 0.37 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -13.3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 12.2 | |||||
| 3-Year EPS without NRI Growth Rate | 1 | |||||
| 3-Year FCF Growth Rate | 20.8 | |||||
| 3-Year Book Growth Rate | -38.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 19.17 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 28.35 | |||||
| 9-Day RSI | 35.16 | |||||
| 14-Day RSI | 38.67 | |||||
| 3-1 Month Momentum % | 9.94 | |||||
| 6-1 Month Momentum % | 26.75 | |||||
| 12-1 Month Momentum % | -6.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.11 | |||||
| Quick Ratio | 3.11 | |||||
| Cash Ratio | 2.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.6 | |||||
| Shareholder Yield % | 2.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -783.96 | |||||
| Net Margin % | -743.79 | |||||
| FCF Margin % | -773.48 | |||||
| ROE % | -151.83 | |||||
| ROA % | -83.3 | |||||
| ROIC % | -921.69 | |||||
| 3-Year ROIIC % | 535.79 | |||||
| ROC (Joel Greenblatt) % | -2740.4 | |||||
| ROCE % | -116.23 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.7 | |||||
| PB Ratio | 3.02 | |||||
| Price-to-Tangible-Book | 3.02 | |||||
| EV-to-EBIT | -0.15 | |||||
| EV-to-Forward-EBIT | -0.01 | |||||
| EV-to-EBITDA | -0.15 | |||||
| EV-to-Forward-EBITDA | -0.02 | |||||
| EV-to-Revenue | 1.15 | |||||
| EV-to-FCF | -0.15 | |||||
| Earnings Yield (Greenblatt) % | -666.67 | |||||
| FCF Yield % | -121.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BCAB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioAtla Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 11 | ||
| EPS (TTM) ($) | -1.7 | ||
| Beta | 0.9 | ||
| 3-Year Sharpe Ratio | -0.18 | ||
| 3-Year Sortino Ratio | -0.33 | ||
| Volatility % | 93.32 | ||
| 14-Day RSI | 38.67 | ||
| 14-Day ATR ($) | 0.148657 | ||
| 20-Day SMA ($) | 1.5635 | ||
| 12-1 Month Momentum % | -6.13 | ||
| 52-Week Range ($) | 1.14 - 4.02 | ||
| Shares Outstanding (Mil) | 48.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioAtla Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioAtla Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
BioAtla Inc Frequently Asked Questions
What is BioAtla Inc(BCAB)'s stock price today?
The current price of BCAB is $1.45. The 52 week high of BCAB is $4.02 and 52 week low is $1.14.
When is next earnings date of BioAtla Inc(BCAB)?
The next earnings date of BioAtla Inc(BCAB) is 2025-03-26 Est..
Does BioAtla Inc(BCAB) pay dividends? If so, how much?
BioAtla Inc(BCAB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers